Browsing by Author "Germanidis, G."

Now showing 1 - 5 of 5

ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS (R)), peginterferon alfa-2a (40KD) plus lamivudine or lamivudine alone
(Wiley, 2004-10) Piratvisuth, T.; Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.M.; Germanidis, G.; Yurdaydın, C.; Diago, M.; Lai, M.Y.; Button, P.; Why, R.D.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Bu çalışma, 29 Ekim- 02 Kasım 2004 tarihleri arasında Boston[Amerika Birleşik Devletleri]’nde düzenlenen 55. Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)’da bildiri olarak sunulmuştur.
First detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B: Data from a multicenter, randomized, partially double-blind study of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine alone
(Wiley, 2004-10) Bonino, F.; Lau, G.; Macellin, P.; Hadziyannis, S.; Kitis, G.; Jin, R.; Yao, G.B.; Piratvisuth, T.; Germanidis, G.; Yurdaydın, Cihan; Diago, M.; Lai, M.; McCloud, P.; Brunetto, M.R.; Farci, P.; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Bilim Dalı.
A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.
(Wiley, 2003-10) Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Lu, Z.; Piratvisuth, T.; Germanidis, G.; Yurdaydın, C.; Diago, M.; Lai, M.; Button, P.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi.; AAH-5364-2019; ABI-3764-2020
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
(Bmj Publishing Group, 2007-05-01) Bonino, F.; Marcellin, P.; Lau, G. K. K.; Hadziyannis, S.; Jin, R.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; Diago, M.; Gürel, S.; Lai, M-Y; Brunetto, M. R.; Farci, P.; Popescu, M.; McCloud, P.; GÜREL, SELİM; 0000-0002-6822-6685; 0000-0002-8928-3769; 0000-0002-5249-9208; 0000-0001-7985-3118; 0000-0003-3848-5130; HLH-8209-2023; ABI-3764-2020; AAH-5364-2019; AAQ-2085-2021; B-7522-2013; AAU-2906-2020; C-6036-2018
Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated.Methods: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20 000 copies/ml.Results: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p < 0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy.Conclusions: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.
Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone
(Wiley, 2004-10) Germanidis, G.; Marcellin, P.; Lau, G.; Bonino, F.; Farci, P.; Hadziyannis, S.; Jin, R.; Yao, G.B.; Piratvisuth, T.; Yurdaydın, C.; Diago, M.; Lai, M.Y.; Popescu, M.; Pluck, N.; Gürel, S.; Uludağ Üniversitesi/Tıp Fakültesi.